SG-001
- Generic Name
- SG-001
A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
Phase 2
Not yet recruiting
- Conditions
- LOCALLY ADVANCED CERVICAL CANCERS
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Chongqing University Cancer Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06981858
Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.
Phase 1
Not yet recruiting
- Conditions
- Unresectable Locally Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 380
- Registration Number
- NCT06682611
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
Phase 1
Not yet recruiting
- Conditions
- Locally Advanced Unresectable Esophageal Squamous Carcinoma
- Interventions
- Radiation: Simultaneous Radiotherapy
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT06136988
- Locations
- 🇨🇳
Shandong Tumor Hospital, Jinan, Shandong, China
🇨🇳Tianjin cancer institute &hospital, Tianjin, Tianjin, China
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Target Recruit Count
- 168
- Registration Number
- NCT06132217
- Locations
- 🇨🇳
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT06089330
A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05508659
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 79
- Registration Number
- NCT05068141
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
Phase 2
Terminated
- Conditions
- Extrahepatic CholangiocarcinomaAdvanced Biliary Tract CancerGallbladder CarcinomaIntrahepatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT05009953
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
Phase 2
- Conditions
- Fallopian Tube CancerEpithelial Ovarian CancerPeritoneal Cancer
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 126
- Registration Number
- NCT04983550
Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT04886700
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath